Drug co-loaded polymer vesicle, and preparation method therefor and use thereof

The preparation of co-loaded drug vesicles through amphiphilic block polymer carriers solved the problems of high side effects of poisoning in the multi-drug combination regimen and poor drug delivery, and achieved efficient and stable packaging and loading of vincristine sulfate and voraseride. Cooperative delivery significantly improved the anti-tumor effect and mouse survival.

WO2024235298A1PCT designated stage expired Publication Date: 2024-11-21SUZHOU UNIV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093819
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing multi-drug combination regimens have problems such as high toxic side effects, large differences in pharmacokinetics and biodistribution, and difficulty in achieving synergistic effects in anti-tumor treatment, especially the proportion of drug delivery and delivery to target sites of different properties is difficult to control. Causes poor anti-tumor effect.

Method used

Using amphiphilic block polymers as carriers, polymer vesicles with co-loaded drugs are prepared by solvent replacement method, combining targeting oncogene Polo-like kinase 1 inhibitors and tubulin inhibitors, such as vincristine sulfate and volts. Laseride forms reversible crosslinked vesicles with asymmetric membrane structures, achieving efficient and stable packing and co-delivery.

Benefits of technology

It significantly improved the anti-tumor effect, avoided the problems of large nanocarrier particle size, poor circulation stability and slow drug release, achieved long circulation of drugs in the blood and rapid release of cells, significantly prolonged the survival of mice, and It has high safety and synergistic anti-tumor activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093819_21112024_PF_FP_ABST
    Figure CN2024093819_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A drug co-loaded polymer vesicle, and a preparation method therefor and the use thereof. A polymer vesicle double-drug nano preparation is obtained by means of the self-assembly and self-crosslinking of an amphiphilic block polymer and the co-loading of anti-tumor drugs at the same time. The drug co-loaded polymer vesicle has the advantages of a simple and controllable preparation, an adjustable drug ratio, a small size, easy storage, high stability, excellent biocompatibility, a rapid and proportional drug release in cells, a strong synergistic anti-tumor effect, high in-vivo safety, being capable of completely eradicating tumors, etc. In general, the polymer vesicle co-loaded with two anti-tumor drugs has multiple advantages, including simple preparation, safety, high efficiency, a synergistic effect, etc., and is expected to greatly improve the treatment effects of malignant tumors, especially acute myeloid leukemia and acute lymphoblastic leukemia.
Need to check novelty before this filing date? Find Prior Art

Description

Drug-co-loaded polymer vesicles and preparation method and application thereof Technical Field

[0001] The present invention belongs to the technical field of polymer nanomedicines, and in particular relates to a drug-co-loaded polymer vesicle and a preparation method and application thereof. Background Art

[0002] The oncogene Polo-like kinase 1 (PLK1) is crucial for tumor cell division and proliferation. It is overexpressed in leukemia and various other tumor types, and its expression level is closely correlated with poor prognosis, significantly promoting the development of molecularly targeted PLK1 drugs. Among them, volacetidine (Vol) is the most advanced PLK1 inhibitor currently in clinical research. In 2013, it received Breakthrough Therapy designation from the FDA for the treatment of patients with acute myeloid leukemia (AML). However, it suffers from issues such as high in vivo clearance, low tumor accumulation, high dosing, severe dose-limiting toxicities, and the development of drug resistance. Its clinical efficacy is limited when used alone, and it usually requires combination with chemotherapy drugs.

[0003] Vincristine sulfate (VCR) is a potent chemotherapy drug that inhibits tubulin polymerization and is widely used in the treatment of malignant blood tumors such as leukemia. However, due to its severe neurotoxicity, the available dosage is relatively low. CN111973556B, the applicant's prior patent application, has all of its disclosures incorporated into the present invention as prior art. It discloses a reversibly cross-linked, degradable polymer vesicle loaded with vincristine sulfate, which is assembled and cross-linked from amphiphilic block polymers. It has an asymmetric membrane structure with an outer shell of polyethylene glycol (PEG), a membrane layer of reversibly cross-linked hydrophobic polycarbonate, and an inner shell of polypeptide KD. z , which can achieve efficient loading of VCR for efficient and specific targeted delivery of vincristine sulfate to multiple myeloma cells. CN110229323A is the applicant's prior patent application, and all its disclosures are incorporated into the present invention as prior art.

[0004] SUMMARY OF THE INVENTION Technical issues

[0005] Compared with monotherapy, dual-drug and multi-drug combination regimens can act on the same signaling pathway or multiple related pathways. However, the current multi-drug combination regimens still face some challenges. On the one hand, multi-drug combinations are usually accompanied by higher toxic side effects. On the other hand, the pharmacokinetics, biodistribution and cell penetration of drugs of different properties vary greatly, making it difficult to deliver them to the target site at the optimal ratio, resulting in poor synergistic effects. The anti-tumor effects of different drug combinations are unpredictable. Maria Sol Brassesco et al. found that the combination of PLK1 inhibitors and doxorubicin had an antagonistic effect (Cancer Biology & Therapy 2013, 14, 648-657); Marta Halasa et al. found that CDDP and CAM had no synergistic effect on MCF7, 47D, MDA-MB-231, and MDA-MB-468, and IC 50 Higher than single drug (Int. J. Mol. Sci. 2021, 22, 8573); According to the studies conducted, polymer-loaded CFZ / MID has almost no synergistic effect on the toxicity of Molm-13-Luc, and the effect is additive or even antagonistic. Therefore, how to achieve efficient and stable encapsulation of multiple drugs with different properties in the same nanocarrier and deliver them to the target at a fixed ratio to exert synergistic effects is also extremely challenging. Technical Solutions

[0006] One object of the present invention is to provide a drug-co-loaded polymer vesicle, which is mainly prepared from an amphiphilic block polymer and two or more anti-tumor drugs, thereby synergistically improving the anti-tumor effect.

[0007] Another object of the present invention is to provide a preparation method and application of drug-co-loaded polymer vesicles.

[0008] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:

[0009] A drug-co-loaded polymer vesicle comprises an amphiphilic block polymer and multiple anti-tumor drugs; preferably, the multiple anti-tumor drugs are two or more different anti-tumor drugs; further preferably, the drug-co-loaded polymer vesicle is prepared from an amphiphilic block polymer and two or more anti-tumor drugs.

[0010] The structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-polypeptide segment.

[0011] Furthermore, the structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-KD z , wherein K is lysine, D is aspartic acid; z is 1 to 20, preferably, z is 5 to 15.

[0012] Furthermore, the structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-AcKD z , wherein K is lysine, D is aspartic acid, Ac is acetyl; z is 1 to 20, preferably, z is 5 to 15.

[0013] Furthermore, at least one of the anti-tumor drugs is a tubulin inhibitor.

[0014] Furthermore, the microtubule inhibitor is any one or more of vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, and eribulin.

[0015] Furthermore, in the provided drug-co-loaded polymer vesicles, at least one of the anti-tumor drugs is an inhibitor targeting the oncogene Polo-like kinase 1.

[0016] Furthermore, the inhibitor targeting oncogene Polo-like kinase 1 is any one or more of volacetide, reglucicetide, ON 01910, BI2536, HMN-214, and GSK461364.

[0017] Furthermore, in the provided drug-co-loaded polymer vesicles, the two or more anti-tumor drugs are a combination of a microtubule inhibitor and an oncogene Polo-like kinase 1 inhibitor.

[0018] Furthermore, the two or more anti-tumor drugs are a combination of vincristine sulfate and volacetidine.

[0019] The mass ratio of the microtubule inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:(1-48); preferably, the mass ratio is 1:(8-32); more preferably, the mass ratio is 1:8, 1:16 or 1:32.

[0020] Furthermore, the hydrophilic segment in the amphiphilic block polymer is a polyethylene glycol segment, and the hydrophobic segment is a random copolymer P(A-DTC), where A is an ester monomer or a carbonate monomer, and DTC is a disulfide five-membered ring carbonate unit; P means polymerization, and P(A-DTC) is a random copolymer of A-DTC.

[0021] Furthermore, the structure of P(A-DTC) is one of the following structures:

[0022] Furthermore, the ester monomer is one or both of caprolactone and lactide; and the carbonate monomer is trimethylene carbonate.

[0023] Furthermore, in the amphiphilic block polymer, the molecular weight of the hydrophilic segment is 2000 to 10000 Da; the molecular weight of the hydrophobic segment is 2 to 10 times that of the hydrophilic segment; the molecular weight of PDTC is 10% to 40% of the total molecular weight of the hydrophobic segment; z is 5 to 15;

[0024] Preferably, the molecular weight of the hydrophilic segment is 2000 to 8000 Da; the molecular weight of the hydrophobic segment is 2 to 6 times that of the hydrophilic segment; the molecular weight of the PDTC segment is 10% to 30% of that of the hydrophobic segment;

[0025] More preferably, the molecular weight of the hydrophilic segment is 5000-7500 Da; the molecular weight of the hydrophobic segment is 2-4 times that of the hydrophilic segment; the molecular weight of PDTC is 10%-20% of the total molecular weight of the hydrophobic segment, and z is 5, 10 or 15.

[0026] Furthermore, the structure of the amphiphilic block polymer is any one of the following structures:

[0027] Furthermore, the drug-co-loaded polymer vesicles are mainly prepared from an amphiphilic block polymer, a tubulin inhibitor, and a targeted oncogene Polo-like kinase 1 inhibitor, wherein the structure of the amphiphilic block polymer is any one of the following structures:

[0028] The microtubule inhibitor is vincristine sulfate, and the inhibitor targeting oncogene Polo-like kinase 1 is volacetide; preferably, the mass ratio of the microtubule inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:1-48.

[0029] Preferably, the mass ratio of the tubulin inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:8-32.

[0030] Preferably, the molecular weight of the hydrophilic segment of the amphiphilic block polymer is 2000-8000 Da; the molecular weight of the hydrophobic segment is 2-6 times that of the hydrophilic segment; and the molecular weight of the PDTC segment is 10%-30% of that of the hydrophobic segment.

[0031] More preferably, the mass ratio of the tubulin inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:8, 1:16 or 1:32.

[0032] More preferably, the molecular weight of the hydrophilic segment is 5000-7500 Da; the molecular weight of the hydrophobic segment is 2-4 times that of the hydrophilic segment; the molecular weight of PDTC is 10%-20% of the total molecular weight of the hydrophobic segment, and z is 5, 10 or 15.

[0033] Furthermore, the present invention provides a method for preparing drug-co-loaded polymer vesicles: using two or more anti-tumor drugs and amphiphilic block polymers as raw materials, the drug-co-loaded polymer vesicles are prepared by a solvent replacement method.

[0034] Furthermore, the preparation method comprises mixing an antitumor drug solution and an amphiphilic block polymer solution, allowing the mixture to stand, and then dialyzing to obtain drug-coated polymer vesicles; the standing time is 5 to 50 hours, preferably 8 to 30 hours.

[0035] Furthermore, the preparation method of reversibly cross-linked degradable polymer vesicles (Ps-VCR / Vol) co-loaded with VCR and Vol is as follows: Vol is mixed with an amphiphilic block polymer (PEG-P(A-DTC)-KD z or PEG-P(A-DTC)-AcKD z ) was added to the stirred VCR solution, and the mixture was dialyzed after standing to obtain Ps-VCR / Vol. Specifically, VCR was dissolved in ultrapure water and mixed evenly with a buffer, such as N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) buffer (HEPES), to obtain a VCR solution; Vol was mixed with an amphiphilic block polymer (PEG-P(A-DTC)-KD z or PEG-P(A-DTC)-AcKD z ) are respectively dissolved in DMSO and mixed evenly, and then the mixture is injected into the VCR solution under stirring, and after continued stirring, it is placed on a shaker and allowed to stand, and then dialyzed with a buffer solution (such as HEPES) to obtain Ps-VCR / Vol, and the mass ratio of VCR to Vol is 1: (8-32).

[0036] The polymer vesicles in the present invention are reduction-sensitive reversibly cross-linked polymer vesicles with negatively charged inner membrane, reversible cross-linking in cells and biodegradable; the polymer is PEG-P(A-DTC)-KD z or PEG-P(A-DTC)-AcKD z , where A (TMC, LA or CL) and DTC in the middle block are randomly arranged; KD z / AcKD z The molecular weight is 700-2000Da, which is much smaller than the molecular weight of the PEG segment. After self-assembly and cross-linking, reversible cross-linked polymer vesicles with negatively charged inner membranes are obtained. The inner shell of the vesicles is KD z or AcKD zUsed for compounding small molecule drugs. The vesicle membrane is a reversibly cross-linked, biodegradable, and highly compatible PTMC, PLA, or PCL. The disulfide ring structure of the side chain is similar to the human body's natural antioxidant lipoic acid, which can spontaneously form reduction-sensitive reversible crosslinks. This not only ensures the stable and long-term circulation of the drug in the blood, but also achieves rapid decrosslinking within the cell, quickly releasing the drug into tumor cells. Compared with the prior art, the KD in the polymer of the present invention has good biocompatibility. Combined with the PEG segment and the hydrophobic segment, it can form an asymmetric membrane structure vesicle, achieving efficient and stable encapsulation of small molecule drugs (such as VCR and Vol). The present invention encapsulates VCR and Vol through electrostatic interaction, while being separated from the outside world by the disulfide cross-linked vesicle membrane, which can avoid leakage and loss and toxic side effects caused by cell adhesion during delivery. It can be efficiently delivered to the lesion site and, under the action of the reducing agent glutathione (GSH) in the body, rapidly releases VCR and Vol, effectively killing tumor cells. Animal experiments showed that Ps-VCR / Vol significantly prolonged the survival of mice, and there was no significant weight loss in mice during treatment.

[0037] Furthermore, the present invention provides the use of the drug-co-loaded polymer vesicles in the preparation of anti-tumor drugs.

[0038] Furthermore, the anti-tumor drug includes a drug for treating acute myeloid leukemia or a drug for treating acute lymphocytic leukemia.

[0039] Furthermore, the present invention provides use of the drug-co-loaded polymer vesicles in treating tumors.

[0040] Furthermore, treating tumors includes treating acute myeloid leukemia or treating acute lymphoblastic leukemia.

[0041] Furthermore, the present invention provides a method for treating tumors, comprising the following steps: treating tumors using the drug-co-loaded polymer vesicles, or treating tumors using the drug-co-loaded polymer vesicles in combination with other drugs.

[0042] Furthermore, treating tumors includes treating acute myeloid leukemia or treating acute lymphoblastic leukemia. Beneficial effects

[0043] Compared with the prior art, the present invention has the following advantages:

[0044] 1. The present invention designs novel drug-loaded vesicles that co-load a microtubule inhibitor and a Polo-like kinase 1 inhibitor targeting the oncogene. The vesicle membrane is made of reversibly cross-linked, biodegradable, and biocompatible polytrimethylene carbonate (PTMC), polylactide (PLA), and polycaprolactone (PCL). The dithiolane side chain provides reduction-sensitive reversible cross-linking, which not only ensures long-term drug circulation in the blood but also allows for rapid intracellular decrosslinking, resulting in the simultaneous release of both drugs into tumor cells.

[0045] 2. The vesicles co-loaded with VCR and Vol disclosed in the present invention have significant synergistic anti-tumor effects in vivo and in vitro. The polymer has good biocompatibility and can form vesicles with asymmetric membrane structures, which have good drug encapsulation and co-delivery effects.

[0046] 3. The degradable polymer vesicle carrier of the present invention avoids the defects of existing nanocarriers such as large particle size, poor in vivo circulation stability, easy drug leakage, and slow intracellular drug release.

[0047] 4. The vesicle system of the present invention possesses numerous unique advantages, including small size, simple and controllable preparation, excellent biocompatibility, high in vivo circulation stability, rapid intracellular drug release, and significant tumor growth inhibition. Therefore, this vesicle system has the potential to become a simple and versatile nanoplatform for the efficient delivery of tubulin inhibitors and targeted oncogene Polo-like kinase 1 inhibitors to tumor cells, exerting a potent synergistic anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 shows PEG-P(TMC-DTC)-KD in Example 1 10 's NMR spectrum.

[0049] Figure 2 shows PEG-P(TMC-DTC)-AcKD in Example 1 10 's NMR spectrum.

[0050] FIG3 is a schematic diagram of the preparation of Ps-VCR / Vol in Example 2.

[0051] Figure 4 shows the PEG-P(TMC-DTC)-KD 10 Particle size and particle size distribution of Ps-VCR / Vol.

[0052] FIG5 shows (A) the changes in particle size and particle size distribution and (B) drug leakage of Ps-VCR / Vol during long-term storage at 4° C. in Example 3.

[0053] Figure 6 shows (A) the stability of Ps-VCR / Vol in Example 3 when diluted 50 times and added with 10% FBS, and (B) the release curve of VCR and Vol in Example 3 under non-reducing conditions and 10 mM GSH.

[0054] Figure 7 shows the PEG-P(TMC-DTC)-KD 10 Anti-AML activities of Ps-VCR / Vol, Ps-VCR, Ps-Vol and freeVCR / Vol in (A), (D) MV-4-11, (B), (E) Molm-13-Luc and (C), (F) WEHI-3 cells (n=6).

[0055] Figure 8 shows the method of Example 4 based on PEG-P(TMC-DTC)-AcKD 10 The anti-AML activities of Ps-VCR / Vol, Ps-VCR, and Ps-Vol in Molm-13-Luc cells (n=6).

[0056] FIG9 shows the anti-AML activity of PS-DNR / Vol in WEHI-3 cells.

[0057] Figure 10 shows the cell cycle analysis of (A) MV-4-11, (B) Molm-13-Luc and (C) WEHI-3 cells in Example 5 after incubation with Ps-VCR / Vol, Ps-VCR, Ps-Vol, freeVCR / Vol and PBS for 24 hours.

[0058] FIG11 shows the apoptosis of (A) MV-4-11, (B) Molm-13-Luc, (C) WEHI-3 cells and (D) primary AML cells induced by Ps-VCR / Vol in Example 5.

[0059] FIG12 shows the effect of Ps-VCR / Vol on the content of related proteins in MV-4-11 and Molm-13-Luc cells in Example 6.

[0060] Figure 13 shows (A) body weight changes, (B) Kaplan-Meier survival curves, and (C) blood biochemistry and routine blood test analysis of mice in each group within 14 days after a single administration of Ps-VCR / Vol in Example 7.

[0061] Figure 14 is a schematic diagram of (A) the establishment, dosing, and monitoring of the orthotopic Molm-13-Luc AML mouse model in Example 8, (B) in vivo bioluminescence imaging images of orthotopic Molm-13-Luc AML mice, (C) semi-quantitative analysis of mouse Luc bioluminescence signals (n=4, the dotted line is the background signal value of healthy mice), (E) Kaplan-Meier survival curve, and (F) changes in mouse weight during treatment.

[0062] Figure 15 shows (A) AML cell infiltration in the liver, lung, spleen, peripheral blood and bone marrow of mice, (B) quantitative analysis and (C) spleen weights of mice in different treatment groups in Example 8.

[0063] Figure 16 is an H&E staining image of the major organs (liver, spleen, kidney, lung and heart) of the in situ Molm-13-Luc mice after different treatments in Example 8.

[0064] Figure 17 shows (A) H&E staining and (B) TRAP staining of the in situ Molm-13-Luc mouse leg bone in Example 8.

[0065] FIG18 shows (A) micro-CT images of the femur and tibia of mice in different treatment groups in Example 8 and (B) quantitative analysis of various indicators.

[0066] Figure 19 is a schematic diagram of (A) the establishment, administration and detection of the orthotopic MV-4-11 or WEHI-3AML mouse model in Example 8, (B) Kaplan-Meier survival curves and (C) weight changes of orthotopic MV-4-11 AML mice after different treatments, and (D) Kaplan-Meier survival curves and (E) weight changes of orthotopic WEHI-3AML mice after different treatments.

[0067] FIG. 20 shows the stability of Ps-VCR / Vol in Example 9 when diluted 100 times and added with 10% FBS.

[0068] Figure 21 shows the results of Example 9 based on PEG-P(TMC-DTC)-KD 10 Toxicity of Ps-VCR in (A) CCRF-CEM and (C) Nalm-6-Luc cells; different ratios of Ps-VCR / Vol and Ps-Vol and free VCR / Vol 1 / 24

[0069] Toxicity in (B) CCRF-CEM and (D) Nalm-6-Luc cells (n=6).

[0070] Figure 22 shows the method of Example 9 based on PEG-P(TMC-DTC)-AcKD 10The anti-ALL activities of Ps-VCR / Vol, Ps-VCR, and Ps-Vol in CCRF-CEM cells (n=6).

[0071] Figure 23 shows the (A, C) CCRF-CEM cells and (B, D) Nalm-6-Luc cells in Example 9 with Ps-VCR / Vol 1 / 24 , Ps-VCR, Ps-Vol, free VCR / Vol 1 / 24 or cell cycle arrest after incubation with PBS for 24 h.

[0072] Figure 24 shows the (A) CCRF-CEM cells and (B) Nalm-6-Luc cells with Ps-VCR / Vol in Example 9. 1 / 24 , Ps-VCR, Ps-Vol and free VCR / Vol 1 / 24 Apoptosis after 48 h of incubation.

[0073] FIG. 25 shows Ps-VCR / Vol in Example 9. 1 / 24 and free VCR / Vol 1 / 24 Toxicity to activated human T cells.

[0074] Figure 26 is a schematic diagram of (A) the establishment, drug administration and monitoring of the orthotopic CCRF-CEM T-ALL mouse model in Example 9; (B) Kaplan-Meier survival curves and (C) body weight changes after different treatments.

[0075] Figure 27 shows (A) representative scatter plots and (B) quantitative analysis of T-ALL infiltration in the peripheral blood of orthotopic CCRF-CEM T-ALL mice after different treatments in Example 9; (C) scatter plots and (D) quantitative analysis of leukemic infiltration in various organs; (E) spleen weights of mice in different treatment groups (n=3).

[0076] FIG28 shows hematoxylin-eosin (H&E) staining images of (A) major organs (liver, spleen, kidney, lung, and heart) and (B) femur and tibia of orthotopic CCRF-CEM mice after different treatments in Example 9.

[0077] Figure 29 shows (A) micro-CT images and (B) quantitative analysis of various indicators of the femur and tibia of mice in different treatment groups in Example 9 (n=3). BMD: bone mineral density; BV / TV: bone volume fraction; BS / TV: bone surface area; Tb.Th: trabecular thickness; Tb.N: trabecular number; Tb.Sp: trabecular separation.

[0078] Figure 30 is a schematic diagram of (A) the establishment, dosing, and monitoring of the patient-derived orthotopic T-ALL PDX mouse model in Example 9; (B) quantitative analysis (n=3) and (C) representative scatter plots of T-ALL infiltration in the peripheral blood of mice after different treatments; (D) Kaplan-Meier survival curves and (E) body weight changes of mice in different treatment groups (n=6).

[0079] Figure 31 is a schematic diagram of (A) the establishment, dosing, and monitoring of the orthotopic Nalm-6-Luc B-ALL mouse model in Example 9; (B) bioluminescence imaging, (C) quantitative analysis, (D) Kaplan-Meier survival curves, and (E) body weight changes after different treatments.

[0080] Figure 32 shows (A) B-ALL infiltration in the liver, spleen, peripheral blood, lung, and bone marrow of each group and (B) quantitative analysis on day 23 after different treatments of orthotopic Nalm-6-Luc B-ALL mice in Example 9; (C) spleen weights of mice in different treatment groups (n=3).

[0081] Figure 33 shows H&E staining images of the major organs (liver, spleen, kidney, lung and heart) as well as the femur and tibia of the orthotopic Nalm-6-Luc mice after different treatments in Example 9. Modes for Carrying Out the Invention

[0082] Unless otherwise specified, the terms used in this document have the following meanings:

[0083] Tubulin inhibitors: Compounds that bind to specific sites on tubulin, affecting and interfering with the dynamics of tubulin polymerization and depolymerization, thereby blocking the formation of the M phase spindle and arresting tumor cell growth at the G2 / M phase, thereby exerting anti-tumor effects. Currently, tubulin inhibitors include vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, and eribulin.

[0084] PLK1 inhibitors: Compounds that inhibit PLK1 activity, resulting in tumor cell growth inhibition or even apoptosis, but with no significant effect on normal cells. Current PLK1 inhibitors include volacetidine, reglucicetidine, ON 01910, BI2536, HMN-214, and GSK461364.

[0085] Random copolymers are copolymers in which the monomer units are randomly arranged along the main chain. If a random copolymer has two monomer units, monomers M1 and M2 are randomly arranged along the macromolecular chain, with the two monomers being randomly distributed along the main chain. In the present invention, the random copolymer is P(A-DTC), where A is an ester monomer or a carbonate monomer unit, and DTC is a disulfide five-membered ring carbonate monomer unit.

[0086] In the present invention, the chemical structural formula of KDz is as follows:

[0087] The chemical structure of AcKDz is as follows:

[0088] z is 1 to 20, preferably 5 to 15. Preferably, z is 5, 10, or 15.

[0089] The definition of the drug for treating acute myeloid leukemia or acute lymphoblastic leukemia in the present invention includes drugs that induce apoptosis of leukemia cells, drugs that prolong the survival of leukemia patients, drugs that reduce tumor infiltration in leukemia patients, etc.

[0090] The present invention is further described below with reference to the examples and accompanying drawings. The specific preparation methods and testing methods are conventional techniques in the art. Cell experiments and animal experiments are conventional experiments that meet the requirements of Soochow University. Unless otherwise specified, in the following examples, the amphiphilic block polymer is PEG 5k -P(TMC 15k -DTC 2k )-KD 10 or PEG 5k -P(TMC 15k -DTC 2k )-AcKD 10 Vincristine sulfate (VCR), volacetidine (Vol) and other reagents are commercially available raw materials, among which KD 10 、AcKD 10 The synthesis was commissioned by Qiangyao Biotechnology Co., Ltd., and the method used was the conventional peptide preparation method in the prior art. 10 It was prepared by Fmoc solid phase synthesis using Fmoc-Lys(Boc)-OH and Fmoc-Asp(otbu)-OH as raw materials. Its purity was 98.4% as determined by HPLC and its molecular weight was 1297.08 as determined by mass spectrometry. 10 Using Fmoc-Lys(Boc)-OH and Fmoc-Asp(otbu)-OH as starting materials, the product was synthesized via Fmoc solid-phase synthesis until the Fmoc protecting group of the last amino acid was removed. Acetylation was then completed by adding DMF solution and 3 equivalents of pyridine / acetic anhydride (1:1) at room temperature for 30 minutes. HPLC analysis revealed a purity of 98.49%, and mass spectrometry revealed a molecular weight of 1339.11.

[0091] Example 1 Polymer PEG-P(TMC-DTC)-KD 10 with PEG-P(TMC-DTC)-AcKD 10 Synthesis

[0092] Polymer PEG-P(TMC-DTC)-KD 10 The terminal hydroxyl group of PEG-P(TMC-DTC) was activated by p-NPC and then reacted with KD 10 The reaction can be obtained by referring to the method disclosed in patent CN201910472613.8 or CN202010845920.9.

[0093] Weigh 85mg KD 10 The polypeptide was placed in a double-necked flask and vacuumed for 1 hour. Then, 3.5 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 153 mg (210 μL) of triethylamine was added. Then, an anhydrous DMSO solution of PEG-P (TMC-DTC) -NPC (755 mg, 7 mL) was added dropwise and reacted at 30°C for 48 hours. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 hours, changing the dialysate every 8 hours, and then dialyzed with DCM for 8 hours, changing it every 4 hours. Finally, it was precipitated in ice ether and vacuum dried for 48 hours to obtain a white flocculent polymer PEG-P (TMC-DTC) -KD 10 , yield: 87%.

[0094] PEG-P(TMC-DTC)-KD 10 of 1 The H NMR spectrum is shown in Figure 1 , where PEG (δ3.23, δ3.49), TMC (δ4.15, δ1.91), DTC (δ4.15, δ3.06) and KD 10 (δ4.47, δ1.15), and by comparing the KD at δ4.47ppm 10 KD was calculated from the peak area of ​​methine and TMC methylene at δ1.91ppm. 10 The grafting rate is 100%.

[0095] Polymer PEG-P(TMC-DTC)-AcKD 10 The terminal hydroxyl group of PEG-P(TMC-DTC) was activated by p-NPC or CDI and then reacted with AcKD 10 Obtained by reaction.

[0096] p-NPC method: Weigh 3g of PEG-P(TMC-DTC) into a two-necked flask and evacuate for 1 hour. Then, under nitrogen, dissolve the mixture in 30mL of anhydrous DCM. Add 54.9μL of pyridine and transfer the mixture to an ice-water bath. Weigh 145mg of p-NPC and dissolve it in DCM to 110mg / mL. Add the mixture dropwise to the reaction flask. After addition, transfer the mixture to room temperature and react for 24 hours. Filter the mixture, collect the filtrate, evaporate it, precipitate it in icy ether, and dry it in vacuum for 48 hours to obtain a white, flocculent polymer, PEG-P(TMC-DTC)-NPC, in an 85% yield.

[0097] PEG-P(TMC-DTC)-NPC and AcKD 10 Peptide reaction: weigh 100mg AcKD 10 The polypeptide was placed in a double-necked flask and vacuumed for 1 hour. 4 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 165 mg (227 μL) of triethylamine was added. PEG-P (TMC-DTC) -NPC in anhydrous DMSO (900 mg, 9 mL) was then added dropwise and reacted at 30°C for 48 hours. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 hours, with the dialysate replaced every 8 hours. It was then dialyzed with DCM for 8 hours, with the dialysate replaced every 4 hours. Finally, the white flocculent polymer PEG-P (TMC-DTC) -AcKD was obtained by precipitation in ice ether and vacuum drying for 48 hours. 10 , yield: 88%.

[0098] CDI method: Weigh 2 g of PEG-P(TMC-DTC) into a two-necked flask and evacuate for 1 hour. Then, dissolve the mixture in 10 mL of anhydrous DCM under nitrogen. Dissolve 55 mg of CDI in 1 mL of DCM and add dropwise to the reaction flask. After complete addition, transfer the mixture to 37°C and react for 4 hours. Finally, precipitate the mixture in glacial tert-butyl methyl ether and dry it in vacuum for 48 hours to obtain a white, flocculent polymer, PEG-P(TMC-DTC)-CDI, with a yield of 90%.

[0099] PEG-P(TMC-DTC)-CDI and AcKD 10 Peptide reaction: weigh 100mg AcKD 10The polypeptide was placed in a double-necked flask and vacuumed for 1 hour. 4 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 165 mg (227 μL) of triethylamine was added. A solution of PEG-P (TMC-DTC) -CDI in anhydrous DMSO (900 mg, 9 mL) was then added dropwise and allowed to react at 30°C for 48 hours. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 hours, with the dialysate replaced every 8 hours. The solution was then dialyzed with DCM for 8 hours, with the dialysate replaced every 4 hours. Finally, the white flocculent polymer PEG-P (TMC-DTC) -AcKD was obtained by precipitation in ice ether and vacuum drying for 48 hours. 10 , yield: 90%.

[0100] PEG-P(TMC-DTC)-AcKD 10 of 1 The H NMR spectrum is shown in Figure 2 , where PEG (δ 3.23, δ 3.49), TMC (δ 4.13, δ 1.95), DTC (δ 4.13, δ 3.07) and AcKD can be observed. 10 (δ8.04, δ4.48, δ2.67, δ1.85, δ1.23), and by comparing the AcKD at δ4.48ppm 10 AcKD was calculated from the peak area of ​​methine and TMC methylene at δ1.95ppm. 10 The grafting rate is 100%.

[0101] KD containing two primary amino groups 10 In comparison, AcKD 10 One of the primary amino groups is modified by acetyl group. There is only one primary amino group. Its reaction with PEG-P(TMC-DTC)-NPC or PEG-P(TMC-DTC)-CDI can be carried out at a fixed point. The reaction site is fixed to reduce the generation of by-products, making PEG-P(TMC-DTC)-AcKD 10 The structure is clearer, which is conducive to subsequent CMC quality control research.

[0102] Example 2 Preparation and Characterization of Ps-VCR / Vol

[0103] Ps-VCR / Vol was prepared by solvent exchange method, in which VCR and Vol were reacted with KD z The electrostatic interactions between the VCR and Vol were observed, and the drug was encapsulated in the hydrophilic inner cavity of the vesicles. The mass ratios of VCR and Vol were 1:8, 1:16, and 1:32, respectively, with the theoretical drug loading capacity (DLC) of Vol being constant at 16.7 wt.%. The preparation diagram is shown in Figure 3.

[0104] Taking 1:16 as an example, 1.75 mL Vol of DMSO solution (20 mg / mL) was mixed with 4.3 mL PEG-P(TMC-DTC)-KD 10 Polymer or PEG-P(TMC-DTC)-AcKD 10 A DMSO solution (40 mg / mL) of the polymer was mixed thoroughly; 0.44 mL of an aqueous solution of VCR (5 mg / mL) was added to 38 mL of a HEPES solution (5 mM, pH 6.8) and mixed thoroughly at 37°C and 300 rpm. The DMSO solution of the polymer and Vol was then uniformly injected into the mixture. Stirring was continued for 15 minutes, and the mixture was transferred to a shaker at 37°C and incubated for 12 hours. Ps-VCR / Vol was then dialyzed against HEPES (5 mM, pH 7.4) (MWCO: 3500 Da) to obtain Ps-VCR / Vol. This was then concentrated by centrifugal ultrafiltration (vivaspin, MWCO: 10 kDa) to a drug-loaded vesicle concentration of 9 mg / mL.

[0105] Drug-loaded vesicles with feed ratios of 1:8 and 1:32 were also prepared as above.

[0106] Based on PEG-P(TMC-DTC)-KD 10 The particle sizes of Ps-VCR / Vol at different drug ratios obtained by polymerization ranged from 27.2 to 29.5 nm, with a particle size distribution of less than 0.1 (Table 1 and Figure 4). The VCR content was calculated by HPLC (mobile phase: methanol:water = 70:30, with 0.15% triethylamine added, and the pH adjusted to 7.0 with phosphoric acid) using absorbance at a wavelength of 298 nm (UV), and the Vol content was calculated by UV-vis spectrophotometry. The results showed that the encapsulation efficiency (DLE) of VCR and Vol was 47.0-49.5% and 71.4-75.4%, respectively. When the mass ratios of VCR to Vol were 1:8, 1:16, and 1:32, respectively, the actual mass ratios of VCR and Vol encapsulated were 1:12.2, 1:24.3, and 1:48.7, respectively, abbreviated as Ps-VCR / Vol. 1 / 12 、Ps-VCR / Vol 1 / 24 and Ps-VCR / Vol 1 / 48 The preparation of Ps-VCR and Ps-Vol was similar to that of Ps-VCR / Vol. Only VCR or Vol was added during the drug encapsulation process. The theoretical DLC of VCR and Vol were 5 wt.% and 16.7 wt.%, respectively. The particle size and particle size distribution of the two were similar to those of Ps-VCR / Vol, and the actual DLC were 4 wt.% and 13.24 wt.%, respectively.

[0107] Table 1 Based on PEG-P(TMC-DTC)-KD10 Characterization of polymer loading with different VCR and Vol mass ratios Ps-VCR / Vol

[0108] a Determined by HPLC; b Measured by UV-vis; c Measured by DLS.

[0109] Based on PEG-P(TMC-DTC)-AcKD 10 The particle sizes of Ps-VCR / Vol prepared with different drug ratios ranged from 28.5 to 29.6 nm, with a particle size distribution less than 0.1. The DLEs of VCR and Vol were 47.1-48.9% and 72.6-73.7%, respectively (Table 2). When the VCR to Vol mass ratios were 1:8, 1:16, and 1:32, respectively, the actual VCR to Vol mass ratios were 1:12.5, 1:24.2, and 1:48.0. The preparations of Ps-VCR and Ps-Vol were similar to those of Ps-VCR / Vol, with only VCR or Vol added during the drug encapsulation process. The theoretical DLCs of VCR and Vol were 5 wt.% and 16.7 wt.%, respectively. Their particle sizes and size distributions were similar to those of Ps-VCR / Vol, with actual DLCs of 4.10 wt.% and 13.27 wt.%, respectively.

[0110] Table 2 Based on PEG-P(TMC-DTC)-AcKD 10 Characterization of polymer loading with different VCR and Vol mass ratios Ps-VCR / Vol

[0111] a Determined by HPLC; b Measured by UV-vis; c Measured by DLS.

[0112] PEG 5k -P(TMC 15k -DTC 2k )-KD 10 Ps-DNR / Vol was prepared using vincristine sulfate (VCR) as the carrier and daunorubicin hydrochloride (DNR) as the drugs. An encapsulation efficiency of 28.4% (Vol) was achieved by loading DNR and Vol at a DNR / Vol ratio of 1:9, and an encapsulation efficiency of 26.4% (Vol) was achieved by loading DNR and Vol at a DNR / Vol ratio of 2:5. The actual DNR / Vol ratio was 1:1.2.

[0113] According to the above method, PEG-P(TMC-DTC)-KDz PEG-P(TMC-DTC)-AcKD z PEG-P(CL-DTC)-KD z PEG-P(CL-DTC)-AcKD z PEG-P(LA-DTC)-KD z PEG-P(LA-DTC)-AcKD z Loading VCR and Vol can achieve an encapsulation rate of more than 40% (VCR) and more than 70% (Vol), such as PEG 5k -P(TMC 10k -DTC 1.5k )-KD 10 / PEG 5k -P(TMC 10k -DTC 1.5k )-AcKD 10 PEG 5k -P(TMC 15k -DTC 2k )-KD 15 / PEG 5k -P(TMC 15k -DTC 2k )-AcKD 15 PEG 5k -P(TMC 15k -DTC 2k )-KD5 / PEG 5k -P(TMC 15k -DTC 2k )-AcKD5、PEG 5k -P(CL 15k -DTC 2k )-KD 10 / PEG 5k -P(CL 15k -DTC 2k )-AcKD 10 PEG 5k -P(LA 15k -DTC 2k )-KD 10 / PEG 5k -P(LA 15k -DTC 2k )-AcKD 10 PEG 7.5k -P(TMC 15k -DTC 2k )-KD 10 / PEG 7.5k -P(TMC 15k -DTC2k )-AcKD 10 .

[0114] Example 3 Stability and in vitro drug release of Ps-VCR / Vol

[0115] In order to study the stability of Ps-VCR / Vol, 1 / 24 For example, the particle size, particle size distribution, and leakage of VCR and Vol were continuously monitored during storage at 4°C. The particle size and particle size distribution were tested on the 30th, 60th, 90th and 300th days. 2 mg Ps-VCR / Vol was taken at 220 and 300 days respectively. 1 / 24 The solution was diluted to 1 mg / mL with HEPES and ultracentrifuged (58,000 rpm, 1 h). The supernatant was tested by HPLC for Vol and VCR concentrations and the amount of drug leakage was calculated. The drug retention (%) was calculated by comparing it with the drug content at day 0. Figures 5A and 5B are Ps-VCR / Vol, respectively. 1 / 24 The particle size, particle size distribution and drug retention of the graph. The results show that Ps-VCR / Vol 1 / 24 The particle size and polydispersity index (PDI) did not change significantly after being stored at 4°C for 300 days, and the drug retention was higher than 95%. In addition, the Ps-VCR / Vol 1 / 24 The particle size distribution after dilution 50 times with PBS and addition of 10% FBS is shown in FIG6A . Ps-VCR / Vol can maintain good stability when diluted 50 times or added with 10% FBS.

[0116] Ps-VCR / Vol 1 / 12 As an example, the drug release of Ps-VCR / Vol was studied by dialysis. 1 / 12 The drug release medium (2 mg / mL) was loaded into a drug release bag (MWCO: 14,000 Da) and placed in 20 mL of HEPES (5 mM, pH 7.4) or HEPES containing 10 mM GSH. The release medium was shaken at 37°C at 200 rpm (n = 3). After 0, 1, 2, 4, 6, 8, 10, 12, and 24 h, 5 mL of the release medium was removed and replaced with 5 mL of fresh release medium. The release medium was freeze-dried and dissolved in 300 μL of a mixture of methanol and secondary water (1:1 volume ratio). The solution was filtered through a 0.22 μm filter and analyzed by HPLC. The mobile phase for VCR was methanol:water (0.15% triethylamine) = 70:30, and the detection wavelength was 298 nm. The mobile phase for Vol was acetonitrile:water (0.15% triethylamine) = 60:40, both adjusted to pH 7.0 with phosphoric acid, and the detection wavelength was 330 nm. Figure 6B shows Ps-VCR / Vol1 / 12 Figure 3 shows the in vitro release results of the dual-drug vesicle nanoformulation. The results show that under physiological conditions, the release of both VCR and Vol from Ps-VCR / Vol was less than 20% within 24 hours. However, in the presence of 10 mM GSH, the release of VCR and Vol reached over 90%, with similar release kinetics, indicating that VCR and Vol can be released in the desired ratio.

[0117] Example 4 In vitro synergistic anti-AML experiment of Ps-VCR / Vol

[0118] The synergistic antitumor activity of Ps-VCR / Vol at different drug ratios in MV-4-11, Molm-13-Luc, and WEHI-3 AML cells was determined using a CCK-8 assay. MV-4-11 and Molm-13-Luc cells were cultured in RPMI-1640 medium containing 10% FBS, 1% penicillin, and streptomycin, while WEHI-3 cells were cultured in DMEM medium (containing 20% ​​FBS, 1% penicillin, and streptomycin). The three cell types were plated in 96-well plates (2×10 4 Each well was added with 20 μL of different concentrations of Ps-VCR, Ps-Vol, Ps-VCR / Vol 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol 1 / 48 (Based on PEG-P(TMC-DTC)-KD 10 Polymer prepared) and free VCR / Vol 1 / 24 , incubated in the incubator for 48 hours. The in-well concentration of VCR in the Ps-VCR group was 0.007-6.8 ng / mL. For the Ps-Vol and dual-drug combination groups, the in-well concentration of Vol was 0.1-500 ng / mL when incubated with Molm-13-Luc and WEHI-3 cells, and 0.1-100 ng / mL when incubated with MV-4-11 cells. After 48 hours of incubation, 10 μL of CCK-8 solution was added to each well, and the incubation was continued for 3 hours. The absorbance at 450 nm was tested using a microplate reader (n=6). The cell viability was the ratio of the absorbance of the sample group cells to the absorbance of the PBS group cells. The synergistic effect of VCR and Vol was evaluated by calculating the Combination Index (CI). That is:

[0119] When CI < 1, there is a synergistic effect, especially when CI < 0.5, it is a strong synergistic effect, especially when CI < 0.3, it is an extremely strong synergistic effect; when CI = 1, it is an additive effect; when CI > 1, it shows an antagonistic effect. The evaluation results are as follows:

[0120] Table 3 Based on PEG-P(TMC-DTC)-KD 10 Synergistic effect of Ps-VCR / Vol with different VCR and Vol mass ratios in AML cells

[0121] The study found that both Ps-VCR and Ps-Vol could effectively inhibit the proliferation of AML cells. 50 The results were 1.3-1.7 ng / mL and 8-21.4 ng / mL respectively (Figure 7 and Table 3). Compared with Ps-VCR and Ps-Vol single-drug vesicles, Ps-VCR / Vol dual-drug vesicle nanoformulations showed significantly enhanced anti-AML activity at the mass ratio of VCR to Vol of 1:12, 1:24 and 1:48. In MV-4-11 cells, the IC values ​​of VCR and Vol of the three were 1:12, 1:24 and 1:48 respectively. 50 The values ​​were 0.032-0.095 ng / mL and 1.3-1.5 ng / mL, respectively, which were only 1 / 13 and 1 / 5 of those of Ps-VCR and Ps-Vol, and the synergistic index (CI) was as low as 0.20-0.25 ( Figure 7A, D and Table 3 ), indicating that VCR and Vol had potent synergistic anti-AML activity when co-loaded, and the adjustable range of drug ratio was wide.

[0122] IC values ​​of Ps-VCR / Vol with different VCR and Vol ratios in Molm-13-Luc cells and WEHI-3 cells 50 Compared with Ps-VCR and Ps-Vol, the CI values ​​were also significantly reduced, with values ​​of 0.36-0.41 and 0.18-0.23, respectively (Figure 7B, C, E, F and Table 3). 1 / 24 The anti-AML activity of the drug was weak, and the IC values ​​of VCR and Vol 50 The values ​​are Ps-VCR / Vol 1 / 24 The results showed that the synergistic effect of the vesicle nanoformulations co-loaded with VCR and Vol was significantly better than that of the free drug combination.

[0123] Based on PEG-P(TMC-DTC)-AcKD 10The synergistic anti-tumor activity of Ps-VCR / Vol with different drug ratios in Molm-13-Luc cells was also determined using the above method. The intra-well concentration of VCR in the Ps-VCR group was 0.1-20 ng / mL, and the intra-well concentration of Vol in the Ps-Vol and dual-drug combination groups was 0.01-100 ng / mL. The anti-AML activity and synergistic effect are shown in Figure 8 and Table 4. The anti-AML activity of Ps-VCR / Vol with different drug ratios was significantly improved compared with Ps-VCR and Ps-Vol. The IC values ​​of VCR and Vol of the three were 0.1-20 ng / mL. 50 The values ​​were 0.09-0.34 ng / mL and 4.1-4.3 ng / mL, respectively, and the CI value was 0.36-0.43, indicating that VCR and Vol had potent synergistic anti-AML activity when co-loaded, and the adjustable range of drug ratio was wide.

[0124] Table 4 Based on PEG-P(TMC-DTC)-AcKD 10 Synergistic effect of Ps-VCR / Vol with different VCR and Vol mass ratios in AML cells

[0125] Referring to the above method, the anti-AML activity of PS-DNR / Vol in WEHI-3 cells is shown in Figure 9 and Table 5, where the drug ratio is the actual ratio. According to calculations, the CI value when DNR and Vol were co-loaded was 1.1-2.4, and DNR and Vol showed antagonistic effects when co-loaded.

[0126] Table 5 Synergistic effect of Ps-DNR / Vol with different DNR and Vol mass ratios in AML cells

[0127] Unless otherwise specified, the Ps-VCR / Vol used in subsequent experiments was based on PEG-P(TMC-DTC)-KD 10 Polymer preparation.

[0128] Example 5 Ps-VCR / Vol synergistically arrests cell cycle and induces apoptosis

[0129] The cell cycle arrest of AML cells by Ps-VCR / Vol was studied by PI / RNase A staining. 1.8 mL of MV-4-11, Molm-13-Luc and WEHI-3 cells were plated into 6-well plates (5×10 5 0.2 mL PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol were added respectively. 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol 1 / 48and free VCR / Vol 1 / 24 . The in-well concentration of VCR in Ps-VCR was 0.4 ng / mL, and the concentration of Vol in other groups was fixed at 10 ng / mL. After incubation in the incubator for 24 hours, the cells were collected by centrifugation and resuspended in 1 mL of ice-cold PBS. The cells were slowly added to 4 mL of 95% ethanol in a vortexed state and fixed at 4°C for 24 hours. Then, the cells were washed with PBS and resuspended in 0.4 mL of staining buffer. 15 μL of PI and 4 μL of RNase A (2.5 mg / mL) were added to each sample group. After staining at 37°C for 30 minutes, they were directly tested by flow cytometry. The results showed that Ps-VCR / Vol with different VCR and Vol mass ratios could effectively induce G2 / M phase arrest of MV-4-11 cells at a Vol concentration of 10 ng / mL. The proportion of cells in the G2 / M phase was significantly increased from 18.9% in the PBS group to 56.2% (Figure 10A, D), while the vesicle single-drug preparation was similar to the PBS group (22%). Furthermore, the free VCR / Vol group induced only 30.8% G2 / M arrest, significantly lower than the Ps-VCR / Vol group. Similarly, in Molm-13-Luc cells, three different ratios of Ps-VCR / Vol induced 60-70% G2 / M arrest, significantly higher than the free VCR / Vol group (20.6%). However, a single-agent formulation of Ps-Vol (Vol: 10 ng / mL) vesicles failed to induce cell cycle arrest, with the G2 / M phase percentage comparable to that of the PBS group (6%). While Ps-VCR (VCR: 0.4 ng / mL) increased G2 / M arrest, the percentage was only 16.9% (Figures 10B, E). In WEHI-3 cells, the three different ratios of Ps-VCR / Vol groups also significantly increased the G2 / M phase percentage compared to the other control groups (Figures 10C, F).

[0130] Both VCR and Vol can induce cell cycle arrest, thereby causing cell apoptosis. To this end, the Annexin V-APC / 7-AAD double staining apoptosis kit was used to further study the apoptosis of AML cells induced by Ps-VCR / Vol. 1.8 mL of MV-4-11, Molm-13-Luc, WEHI-3, and primary cells extracted from the bone marrow of AML patients were plated into 6-well plates (5×10 5 1 / well), add 0.2mL PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, respectively. 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol 1 / 48 and Free VCR / Vol 1 / 24. The concentration of Ps-VCR in the VCR wells of the three cell lines was 0.4 ng / mL, and the concentration of Vol in other groups was constant at 10 ng / mL. In the patient's primary cells, the concentrations of VCR and Vol were 0.2 and 4.8 μg / mL, respectively. After incubation in the incubator for 48 hours, the cells were collected by centrifugation, resuspended with 0.5 mL 1×binding buffer, and 5 μL Annexin V-APC and 10 μL 7-AAD were added to each well. After staining at room temperature for 5 minutes, the cells were tested by flow cytometry. At least 10,000 cells were collected for each sample. The results showed that in MV-4-11 cells, Ps-VCR / Vol at three different drug ratios could cause significant cell apoptosis, with an apoptosis rate higher than 90%, among which Ps-VCR / Vol 1 / 24 The highest level in the group was 99.7%, which was significantly higher than Ps-VCR (49.2%), Ps-Vol (36%) and free VCR / Vol 1 / 24 group (62.6%) (Figure 11A). In Molm-13-Luc cells, Ps-VCR / Vol 1 / 12 、Ps-VCR / Vol 1 / 24 and Ps-VCR / Vol 1 / 48 It resulted in approximately 75% cell apoptosis, compared to Ps-VCR (34.3%) and Ps-Vol (32.5%) vesicle monotherapy and free VCR / Vol 1 / 24 When WEHI-3 cells were incubated with different Ps-VCR / Vol for 48 h, about 70% of the cells underwent apoptosis, which was significantly improved compared with Ps-VCR (32.6%), Ps-Vol (26.9%) and free VCR / Vol. 1 / 24 (36.3%) was increased by 2.1-2.7 times (Figure 11C). 1 / 24 It also has a significant ability to promote apoptosis in primary patient specimen cells. In 8 patient specimens, it showed a significantly higher apoptosis rate than other control groups (Ps-VCR, Ps-Vol and free VCR / Vol). 1 / 24 ) showed the strongest anti-tumor activity (Figure 11D). Thus, Ps-VCR / Vol at three drug ratios (1:12, 1:24, and 1:48) was able to effectively induce AML cells to arrest in the G2 / M phase, thereby promoting cell apoptosis. The effect was significantly better than that of Ps-VCR and Ps-Vol vesicles alone, as well as free VCR / Vol, showing a significant synergistic effect.

[0131] Example 6: Western blot study of the inhibitory effect of Ps-VCR / Vol on AML cell protein expression

[0132] In order to study the synergistic anti-AML mechanism of VCR and Vol, the expression of related proteins was characterized by immunoblotting. 1.8 mL of Molm-13-Luc and MV-4-11 cell suspension (1×10 6 pcs / well) were plated in a 12-well plate, and 0.2 mL of PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol were added. 1 / 24 or free VCR / Vol 1 / 24 , so that the in-well concentrations of VCR and Vol were 0.2 ng / mL and 4.8 ng / mL, respectively. After incubation in the incubator for 48 hours, the cells were washed with ice-cold PBS and lysed on ice for 20 minutes in 100 μL of ice-cold RIPA lysis buffer. The precipitate was then removed by centrifugation (4°C, 12,000 rpm) for 15 minutes, and the total protein concentration was determined using BCA assay. A 20% volume fraction of loading buffer was added to the protein, and the cells were boiled in a 95°C water bath for 5 minutes. Twenty μg of protein from each sample group was separated by 10% SDS-PAGE electrophoresis. The proteins were then transferred to a PVDF membrane and blocked with 5% skim milk in TBST for 2 hours at room temperature. Bands of appropriate molecular weight were excised and incubated with antibodies against MCL-1, BCL-2, pHH3, and β3-tubulin, respectively, and incubated overnight at 4°C. The strips were washed three times with Tris-HCl buffer solution / 0.1% Tween-20 (TBST) and incubated with HRP-labeled secondary antibody at room temperature for 1.5 hours. After the strips were treated with developer, images were obtained using an electrochemiluminescence detection system (Pierce). Figure 12 shows the immunoblotting results. The results showed that Ps-VCR / Vol 1 / 24 Treatment can significantly downregulate the expression of two anti-apoptotic proteins, MCL-1 and BCL-2, while upregulating the expression of effector Caspase-3 protein, activating the pro-apoptotic pathway, and the effect is significantly better than that of vesicle single-drug preparations and free VCR / Vol 1 / 24 In summary, Ps-VCR / Vol exerts synergistic anti-AML activity by synergistically arresting cells in the G2 / M phase, downregulating the anti-apoptotic proteins BCL-2 and MCL-1, adjusting the balance between pro-apoptotic and anti-apoptotic proteins of the BCL-2 family, activating caspase-dependent effector pathways, and initiating mitochondrial apoptosis.

[0133] Example 7 In vivo acute toxicity experiment of Ps-VCR / Vol

[0134] The acute toxicity of Ps-VCR / Vol in vivo was studied using Kunming mice (Weitong Lihua, 6 weeks old, half male and half female). The mice were randomly divided into 3 groups, 10 mice in each group, half male and half female, and Ps-VCR / Vol was injected once through the tail vein. 1 / 12(1mg VCR&12mg Vol equiv. / kg), Ps-VCR / Vol 1 / 24 (1mg VCR&24mg Vol equiv. / kg), Ps-VCR / Vol 1 / 48 (0.5mg VCR & 24mg Vol equiv. / kg). The body weight, condition and survival of the mice were continuously monitored for 14 days after administration. On the 5th day after administration, 4 mice (2 females and 2 males) were randomly selected from each group and blood samples were collected from the abdominal aorta for blood routine and blood biochemistry tests. 4 healthy mice that were not given the drug were used as controls. The results showed that Ps-VCR / Vol 1 / 48 When the doses of VCR and Vol were 0.5 and 24 mg / kg respectively, the body weight of mice in the Ps-VCR / Vol group did not decrease, but continued to grow, and there was no abnormality in their posture and behavior. 1 / 12 The body weight of mice in the (1mg VCR & 12mg Vol equiv. / kg) group decreased slightly (<5%) within 2 days after administration, and then quickly returned to normal. No obvious toxicity or death was observed. 1 / 24 For the 1mg VCR & 24mg Vol equiv. / kg group, although the mice experienced a decrease in body weight (~8%) within 3 days after administration, and one mouse (1 / 10) showed signs of sluggishness, these mice recovered rapidly starting on day 4, with no deaths due to toxicity (Figures 13A, B). Furthermore, blood routine and biochemical parameters in all groups were within normal ranges, showing no significant differences compared to healthy mice (Figure 13C), demonstrating that the three different drug ratios of Ps-VCR / Vol exhibited a high safety profile, even at high doses, and were significantly superior to the free drug.

[0135] Example 8 Synergistic Anti-AML Activity of Ps-VCR / Vol in Vivo

[0136] The in vivo synergistic anti-AML activity of Ps-VCR / Vol was studied using three AML mouse models bearing orthotopic Molm-13-Luc, MV-4-11 and WEHI-3.

[0137] To establish the in situ Molm-13-Luc model, 200 μL Molm-13-Luc cell suspension (5×10 5 ) were injected into 6-week-old NOD.CB17-Prkdc cells via tail vein scid / IL2rg tm1 / Bcgen (B-NDG) female mice, and the day of inoculation was recorded as day 0. On the 3rd day after inoculation, the orthotopic Molm-13-Luc AML mouse model was randomly divided into 7 groups and injected with PBS, Ps-VCR (0.25mg VCR equiv. / kg), Ps-Vol (6mg Vol equiv. / kg), Ps-VCR / Vol through the tail vein. 1 / 12 (0.25mg VCR&3mg Vol equiv. / kg), Ps-VCR / Vol 1 / 24 (0.25mg VCR&6mg Vol equiv. / kg), Ps-VCR / Vol 1 / 48 (0.125mg VCR & 6mg Vol equiv. / kg) and free VCR / Vol 1 / 24 (0.25mg VCR & 6mg Vol / kg), once every 3 days, for a total of 4 injections (Figure 14A). There were 13 mice in each group, 6 for body weight and survival monitoring, 4 for imaging monitoring of tumor growth, and 3 for detecting tumor infiltration and micro-CT and other analyses. The study found that the mice in the PBS group developed the disease rapidly, and symptoms such as hind limb paralysis and poor spirits appeared around the 15th day after inoculation, and died (Figure 14B-E). Ps-VCR / Vol with three different drug ratios can effectively inhibit the proliferation of Molm-13-Luc cells in mice. No tumor-related bioluminescent signals were observed within 20 days after the end of administration (on the 32nd day). Among them, Ps-VCR / Vol 1 / 24 The best effect was achieved, with no obvious signal observed at the end of imaging on day 44, and the Luc signal intensity was comparable to that of healthy mice (Figure 14B-D). However, the AML cells in the Ps-Vol and Ps-VCR vesicle single-agent groups proliferated rapidly after administration, with the tumor Luc bioluminescence signal on day 22 increasing by 235 and 5.6 times, respectively, compared to that on day 7. 1 / 24 Although the proliferation of Molm-13-Luc cells was suppressed in the early stage, recurrence occurred on the 32nd day, and the tumor Luc signal increased rapidly. On the 38th day, the tumor Luc signal increased significantly compared with the Ps-VCR / Vol 1 / 24 The free VCR / Vol 1 / 24 All mice in the Ps-VCR / Vol group died within 46 days, with a median survival time (MST) of 44 days. 1 / 24All mice in the group were cured, and no symptoms or deaths occurred during the 180-day observation period, which was more than 6.7 times longer than that of the Ps-VCR (MST: 27 days) and Ps-Vol (MST: 24 days) vesicle single-drug preparation groups, and more than 11 times longer than that of the PBS group (MST: 16 days) (Figure 14E). 1 / 12 and Ps-VCR / Vo 1 / 48 At lower doses of Vol and VCR, the survival of mice was significantly prolonged, with MST of 55 and 52 days, respectively, which was more than 3.2 times longer than that of the PBS group. 1 / 24 The body weight of mice in the 14 groups decreased by 8%, indicating mild toxicity, while the body weights of mice in the other groups showed no significant abnormalities (Figure 14F). These results indicate that Ps-VCR / Vol has good safety and excellent synergistic antitumor activity in the orthotopic Molm-13-Luc AML model. 1 / 24 The anti-AML activity was the strongest and a complete cure was achieved.

[0138] On day 43 after inoculation, sacrifice Ps-VCR / Vol 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol 1 / 48 The treatment group was used to detect 3 mice for infiltration, and the liver, spleen, lung, bone marrow (BM) and peripheral blood (PB) were collected to test the tumor cell infiltration (n=3). At the same time, the heart, liver, spleen, lung, kidney and other major organs and hind leg bones were collected and fixed with 4% paraformaldehyde and embedded in paraffin, and histological and osteoclast analysis was performed by H&E and TRAP staining. On the 15th day after inoculation, the PBS group mice were sacrificed as a control. The Ps-VCR and Ps-Vol groups sacrificed mice at the end of the experiment to collect the main organs / tissues for analysis. Consistent with the imaging results, Ps-VCR / Vol 1 / 24 No leukemia cells were found in the organs of the mice in the Ps-VCR / Vol group, and the spleen weight was similar to that of healthy mice (Figure 15), further indicating that the Ps-VCR / Vol group effectively eliminated leukemia cells in the mice. 1 / 12 and Ps-VCR / Vol 1 / 48 Although the leukemia cell infiltration rate of each organ in the mice of group A was significantly lower than that in the PBS group, there was obvious leukemia cell infiltration in all organs, among which Ps-VCR / Vol 1 / 12 The infiltration rates of the liver, spleen, lung and bone marrow of the two groups of mice were 47%, 9%, 22.8% and 17% respectively (Figure 15A, B). In addition, the spleen weight of the two groups of mice was significantly higher than that of the Ps-VCR / Vol 1 / 24 The WT and healthy mice also showed significant increases (Figure 15C).

[0139] H&E staining images showed that the liver, spleen, kidney and lung of mice in the PBS group were almost completely invaded by AML cells. Although the number of AML cells in the liver, spleen, kidney and lung of mice in the Ps-VCR and Ps-Vol groups was reduced to a certain extent compared with the PBS group, a large number of AML cells were still present in the liver. Normal cells in the spleen and lungs were almost completely replaced by AML. A small amount of tumor infiltration was also present in the kidney, indicating severe organ damage. 1 / 12 and Ps-VCR / Vol 1 / 48 After treatment, the infiltration of leukemia cells in the liver and spleen was significantly inhibited. A small amount of leukemia cells still remained in the liver and spleen of mice, while Ps-VCR / Vol 1 / 24 No obvious leukemia cells were found in the organs of the PBS, Ps-Vol and Ps-VCR groups. No toxicity-related damage was found in the major organs of the groups (Figure 16). In the leg bones of mice in the PBS, Ps-Vol and Ps-VCR groups, leukemia cells filled the entire bone marrow cavity, almost completely replacing normal bone marrow cells, and a large number of hematopoietic cells were lost. 1 / 12 and Ps-VCR / Vol 1 / 48 The leukemia cells in the leg bones of mice in the Ps-VCR / Vol group were significantly reduced compared with those in the vesicle single-drug preparation group, but they were still visible. 1 / 24 The hematopoietic cells in the leg bones were normal, and no leukemia cells were found (Figure 17A). The above results were consistent with the infiltration results measured by flow cytometry. The massive proliferation of tumor cells in the bone marrow cavity will cause excessive pressure in the bone marrow cavity and cause bone pain. In addition, NF-κB receptor activating ligand (RANKL) can activate osteoclasts, enhance bone resorption, and cause bone destruction. AML cells inhibit osteoprotegerin that can block RANKL, leading to abnormal activation of osteoclasts and causing bone loss and osteoporosis. Tartrate-resistant acid phosphatase (TRAP) staining and micro-CT were used to evaluate the changes in the bone microenvironment of each group of mice. From the TRAP staining images, it was found that the number of osteoclasts in the PBS and vesicle monotherapy groups increased abnormally, and the number of osteoclasts in the leg bones of mice in the Ps-VCR / Vol groups decreased significantly, especially in the Ps-VCR / Vol groups. 1 / 24 The results of the two groups were consistent with those of healthy mice (Figure 17B). Micro-CT images also showed that the trabeculae in the femoral and tibial medullary cavities of the PBS group disappeared significantly, and there was osteolysis in the cortical bone. Although the trabeculae in the Ps-VCR and Ps-Vol vesicle monotherapy groups were improved compared with the PBS group, they were still at a low level. 1 / 24 It can significantly improve bone damage (Figure 18A). After treatment with Ps-VCR / Vol, the bone mineral density, bone volume fraction, bone surface area, trabecular thickness, and trabecular number of the mouse leg bones were significantly increased, and the trabecular separation was reduced. 1 / 24 The vesicle group showed no difference from healthy mice, while the vesicle group showed only slight improvement compared with PBS ( FIG18B ).

[0140] To further verify the synergistic anti-AML effect of Ps-VCR / Vol in vivo, orthotopic MV-4-11 and WEHI-3 AML mouse models were established. The orthotopic MV-4-11 AML mouse model was established in the same manner as Molm-13-Luc. To establish the orthotopic WEHI-3 AML mouse model, 200 μL of WEHI-3 AML cell suspension (5×10 6 The 100 mg / kg PBS was injected into 6-week-old BALB / c female mice via the tail vein. The day of inoculation was recorded as day 0. The mice bearing orthotopic MV-4-11 and WEHI-3 AML were divided into groups and given PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, and Ps-VCR / Vol on day 3 after inoculation. 1 / 24 and Ps-VCR / Vol 1 / 48 The dosage and frequency of administration were consistent with those in the orthotopic Molm-13-Luc mouse model (Figure 19A). The weight and survival of mice were continuously monitored during and after the administration. The study found that the orthotopic MV-4-11AML mice were highly malignant and developed rapidly. The MST of the PBS group was 20 days. The efficacy of the Ps-VCR and Ps-Vol vesicle monotherapy groups was limited, and the median survival was only slightly extended, with MST of 26.5 and 25 days, respectively (Figure 19B). However, Ps-VCR / Vol 1 / 24 and Ps-VCR / Vol 1 / 48 The treatment effectively eliminated leukemia cells in the mice, and there was no symptom for 180 days, achieving complete cure. The survival period was extended by more than 7 and 9 times compared with the vesicle monotherapy and PBS groups, respectively (***p<0.001). 1 / 24 and Ps-VCR / Vol 1 / 48 Both of them effectively prolonged the survival of mice. At 180 days, Ps-VCR / Vol 1 / 24 All mice in the group survived, and Ps-VCR / Vol 1 / 48 Half of the mice in the group were still alive, and the median survival time had not yet been reached. This was significantly prolonged compared to the Ps-VCR (MST: 57 days), Ps-Vol (MST: 53 days), and PBS (40 days) groups (***p<0.001) (Figure 19D). Importantly, during the treatment period, there was no significant weight loss in the mice in any group (Figures 19C, E), indicating that Ps-VCR / Vol has good in vivo safety. The above results show that Ps-VCR / Vol has potent synergistic anti-AML activity in vivo, achieving complete cure in three different orthotopic AML models.

[0141] Example 9 In vitro synergistic anti-ALL experiment of Ps-VCR / Vol

[0142] Taking 1:16 as an example, 1.75 mL Vol of DMSO solution (20 mg / mL) was mixed with 4.3 mL PEG-P(TMC-DTC)-KD 10 A DMSO solution (40 mg / mL) was mixed thoroughly; 0.44 mL of a 5 mg / mL aqueous solution of VCR was added to 38 mL of a 5 mM HEPES solution (pH 6.8), mixed thoroughly at 37°C and 300 rpm. The polymer and Vol DMSO solutions were then uniformly injected into the mixture, stirred for 15 minutes, and then transferred to a 37°C shaker for incubation for 12 hours. Ps-VCR / Vol was then obtained by extensive dialysis against HEPES (5 mM, pH 7.4) (MWCO: 3500 Da). The product was then concentrated by centrifugal ultrafiltration (vivaspin, MWCO: 10 kDa) to a vesicle concentration of approximately 9 mg / mL. The VCR content was calculated by HPLC (the mobile phase was methanol / water (with 0.15% triethylamine added, pH adjusted to 7.0 with phosphoric acid) = 70:30) based on absorbance at a wavelength of 298 nm (UV). The Vol content was calculated by UV-vis spectrophotometry. The results showed that when the mass ratio of VCR to Vol was 1:16, the encapsulation efficiency (DLE) of VCR and Vol was 48.8% and 75.8%, respectively. The actual encapsulation mass ratio of VCR to Vol was 1:24.8, abbreviated as Ps-VCR / Vol. 1 / 24 , with good dilution and serum stability (Figure 20). Similarly, when the mass ratio of VCR to Vol was 1:8 and 1:32, Ps-VCR / Vol was prepared respectively. 1 / 12 and Ps-VCR / Vol 1 / 48 The preparation of Ps-VCR and Ps-Vol was similar to that of Ps-VCR / Vol, except that only VCR or Vol was added during the drug encapsulation process.

[0143] 1. Synergistic effect of Ps-VCR / Vol in ALL cells. The synergistic antitumor activity of Ps-VCR / Vol at different drug ratios in CCRF-CEM T-ALL and Nalm-6-Luc B-ALL cells was determined using a CCK-8 assay. Cells were cultured in RPMI-1640 medium containing 10% FBS, 1% penicillin, and streptomycin. CCRF-CEM and Nalm-6-Luc cells were plated in 96-well plates (2×10 4 Each well was added with 20 μL of different concentrations of Ps-VCR, Ps-Vol, Ps-VCR / Vol 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol1 / 48 and free VCR / Vol 1 / 24 , incubated in an incubator for 48 hours. The in-well concentration of VCR in the Ps-VCR group was 0.01-100 ng / mL, and for the Ps-Vol and dual-drug combination groups, the in-well concentration of Vol was 0.5-50 ng / mL. After 48 hours of incubation, 10 μL of CCK-8 solution was added to each well, and the absorbance at 450 nm was measured using a microplate reader after another 4 hours of incubation (n=6). The cell viability was the ratio of the absorbance of the sample group cells to the absorbance of the PBS group cells. The synergistic effect of VCR and Vol was evaluated by calculating the Combination Index (CI). When CI < 1, it was a synergistic effect, when CI < 0.7, it was a strong synergistic effect, when CI = 1, it was an additive effect, and when CI > 1, it was an antagonistic effect.

[0144] Figure 21 shows the results of Ps-VCR / Vol synergistically inhibiting the proliferation of CCRF-CEM and Nalm-6-Luc cells. The study found that both Ps-VCR and Ps-Vol can effectively inhibit the proliferation of CCRF-CEM cells. 50 The concentrations of Ps-VCR / Vol in the dual-drug vesicles were 1.94 ng / mL and 16.98 ng / mL, respectively (Figure 21A and Table 6). Compared with Ps-VCR and Ps-Vol single-drug vesicles, the Ps-VCR / Vol dual-drug vesicles exhibited significantly enhanced synergistic anti-ALL activity at VCR to Vol mass ratios of 1:12, 1:24, and 1:48, with CI values ​​of 0.46, 0.46, and 0.47, respectively. 1 / 24 The anti-ALL activity is weak, and the IC 50 The value is Ps-VCR / Vol 1 / 24 3.3 times higher.

[0145] Similarly, the Ps-VCR / Vol dual-drug vesicle formulation also exhibited significant synergistic anti-ALL activity in Nalm-6-Luc cells. When the mass ratio of VCR to Vol was 1:12, 1:24, and 1:48, the CI values ​​were 0.48, 0.32, and 0.54, respectively (Figure 21B and Table 6). Among them, the synergistic effect was strongest when the ratio of VCR to Vol was 1:24, with an IC of VCR to Vol of 0. 50 The values ​​were reduced by 23.4 times and 3.6 times respectively compared with the single drug vesicle preparation. 1 / 24 The anti-ALL activity is weak, and the IC 50 The value is Ps-VCR / Vol 1 / 24 This indicates that the synergistic effect of the vesicle preparation co-loaded with VCR and Vol is significantly better than that of the free drug combination.

[0146] Table 6 Different VCR and Vol mass ratios based on PEG-P(TMC-DTC)-KD 10 Synergistic effect of prepared Ps-VCR / Vol in ALL cells

[0147] Based on PEG-P(TMC-DTC)-AcKD 10 The synergistic antitumor activity of Ps-VCR / Vol at different drug ratios in CCRF-CEM cells was also determined using the above method. The in-well concentration of VCR in the Ps-VCR group was 0.01-100 ng / mL, while the in-well concentration of Vol in the Ps-Vol and dual-drug combination groups was 0.1-200 ng / mL. The results are shown in Figure 22 and Table 7. The anti-ALL activity of Ps-VCR / Vol at different drug ratios was significantly improved compared to that of Ps-VCR and Ps-Vol. The IC values ​​of VCR and Vol for the three groups were 0.01-100 ng / mL. 50 The values ​​were 0.14-0.42 ng / mL and 4.98-6.69 ng / mL, respectively, and the CI values ​​were 0.48-0.51, respectively.

[0148] Table 7 Based on PEG-P(TMC-DTC)-AcKD 10 Synergistic effect of Ps-VCR / Vol with different VCR and Vol mass ratios in CCRF-CEM ALL cells

[0149] 2. Ps-VCR / Vol 1 / 24 Induces cell cycle arrest in ALL.

[0150] Ps-VCR / Vol 1 / 24 The induction of ALL cell cycle arrest was studied by PI / RNase A staining. 1.8 mL of CCRF-CEM or Nalm-6-Luc cells were plated into 6-well plates (5 × 10 5 1 / well), add 0.2mL PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, respectively. 1 / 24 and free VCR / Vol 1 / 24. The in-well concentration of VCR in Ps-VCR is 0.42 ng / mL, and the concentration of Vol in other groups is fixed at 10 ng / mL. After incubation in the incubator for 24 hours, the cells were collected by centrifugation and resuspended with 1 mL of ice PBS. The cells were slowly added to 4 mL of 95% ethanol in a vortex state and fixed at 4°C for 24 hours. Then, the cells were washed with PBS and resuspended with 0.4 mL of staining buffer. 15 μL of PI and 4 μL of RNase A (2.5 mg / mL) were added to each sample group. After staining at 37°C for 30 minutes, the cells were directly tested by flow cytometry. The results showed that in CCRF-CEM cells, Ps-VCR / Vol 1 / 24 When the concentration of Vol was 10 ng / mL, it could effectively induce G2 / M phase arrest of cells, and the proportion of cells in G2 / M phase increased significantly from 8.0% in the PBS group to 46.7%, while the proportion of cells in G2 / M phase of the vesicle single-drug preparations Ps-VCR and Ps-Vol were 11.2% and 22.1%, respectively (Figure 23A, C). 1 / 24 The group also induced only 12.9% G2 / M arrest, which was significantly lower than that of Ps-VCR / Vol 1 / 24 In Nalm-6-Luc cells, Ps-VCR / Vol 1 / 24 The proportion of G2 / M phase cells in the PBS group increased significantly from 23.0% in the PBS group to 50.8%, which was significantly higher than that of the single-drug vesicle preparations Ps-VCR (28.4%) and Ps-Vol (22.8%), as well as free VCR / Vol 1 / 24 (22.6%) (Fig. 23B, D).

[0151] 3. Ps-VCR / Vol 1 / 24 Induces apoptosis in ALL cells

[0152] Both VCR and Vol can induce cell cycle arrest, thus causing cell apoptosis. Therefore, we further used the Annexin V-APC / 7-AAD double staining apoptosis kit to study the Ps-VCR / Vol 1 / 24 Induction of apoptosis in ALL cells. 1.8 mL CCRF-CEM or Nalm-6-Luc cells were plated into 6-well plates (5 × 10 5 pores / well), and 0.2 mL of PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol were added respectively. 1 / 24 and free VCR / Vol 1 / 24The concentration of Ps-VCR in the VCR well was 0.21 ng / mL, and the concentration of Vol in other groups was constant at 5 ng / mL. After incubation in the incubator for 48 hours, the cells were collected by centrifugation and resuspended with 0.5 mL 1× binding buffer. 5 μL Annexin V-APC and 10 μL 7-AAD were added to each well. After staining at room temperature for 5 minutes, the cells were tested by flow cytometry. At least 10,000 cells were collected for each sample. The results showed that in CCRF-CEM cells, the dual-drug vesicle preparation Ps-VCR / Vol 1 / 24 It can induce significant cell apoptosis, with an apoptosis rate of 48.4%, which is significantly higher than that of Ps-VCR (12.5%), Ps-Vol (20.2%) and free VCR / Vol 1 / 24 In Nalm-6-Luc cells, the dual-drug vesicle formulation Ps-VCR / Vol 1 / 24 It can also effectively induce cell apoptosis, with an apoptosis rate of up to 80.8%, which is significantly higher than that of Ps-VCR (44.2%), Ps-Vol (22.7%) and free VCR / Vol 1 / 24 group (14.0%) (Figure 24B). 1 / 24 It can effectively induce ALL cells to arrest in the G2 / M phase, thereby promoting cell apoptosis, and its effect is significantly better than that of Ps-VCR and Ps-Vol vesicle single-drug preparations and free VCR / Vol 1 / 24 , with obvious synergistic effects.

[0153] 4. Ps-VCR / Vol 1 / 24 Cytotoxicity to normal human T cells

[0154] In order to study Ps-VCR / Vol 1 / 24 and free VCR / Vol 1 / 24 The killing effect on normal human cells was determined by CCK-8 kit to determine Ps-VCR / Vol 1 / 24 and free VCR / Vol 1 / 24 Killing effect on activated human T cells. Activated human T cells were cultured in T cell culture medium containing IL-7, IL-10 and Transact. Activated human T cells were plated in 96-well plates (2×10 4 Each well was added with 20 μL of Ps-VCR / Vol 1 / 24 With free VCR / Vol 1 / 24, incubated in an incubator for 48 hours. The concentration of Vol in the wells was 1-100 ng / mL. After incubation for 48 hours, 10 μL of CCK-8 solution was added to each well, and the absorbance at 450 nm was tested using a microplate reader after further incubation for 4 hours (n=6). The cell viability was the ratio of the absorbance of the sample group cells to the absorbance of the PBS group cells. The results showed that when the concentration of Vol was as high as 100 ng / mL, Ps-VCR / Vol 1 / 24 The cell survival rate of the group was still 89%, while the free VCR / Vol 1 / 24 When the Vol concentration was 50 ng / mL, the cell survival rate was only about 50% ( FIG. 25 ), indicating that Ps-VCR / Vol had no obvious toxicity to normal human T cells and had good safety.

[0155] 5. Ps-VCR / Vol 1 / 24 Synergistic anti-T-ALL activity in vivo

[0156] All animal experiments were approved by the Experimental Animal Center of Soochow University and the Suzhou Animal Care and Use Committee, and all animal experimental procedures complied with the animal care and use regulations of Soochow University. 1 / 24 The in vivo synergistic anti-T-ALL activity of α-glucan was investigated using an orthotopic CCRF-CEM-bearing (T-ALL CDX) mouse model and a patient-derived T-ALL xenograft (PDX) model.

[0157] To establish the in situ CCRF-CEM model, 200 μL CCRF-CEM cell suspension (5×10 5 ) were injected into 7-8 week old NOD / ShiLtJGpt-Prkdc cells via tail vein em26Cd52 Il2rg em26Cd22 / Gpt(NCG) female mice, and the day of inoculation was recorded as day 0. On the 5th day after inoculation, the orthotopic CCRF-CEM mouse model was randomly divided into 5 groups and injected with PBS, Ps-VCR (0.25mg VCR equiv. / kg), Ps-Vol (6mg Vol equiv. / kg), Ps-VCR / Vol through the tail vein, respectively. 1 / 24 (0.25mg VCR&6mg Vol equiv. / kg) and free VCR / Vol 1 / 24 (0.25mg VCR & 6mg Vol / kg), once every 4 days, for a total of 5 injections (Figure 26A). Each group consisted of 10 mice, 6 of which were used for body weight and survival monitoring, and 4 for tumor infiltration and micro-CT analysis. During the treatment period, free VCR / Vol 1 / 24The body weight of mice in the PBS group decreased by 25.2%, and one mouse died. The body weight of mice in the other groups did not decrease significantly (Figure 26C). It was also observed that the mice in the PBS group developed symptoms rapidly, such as hind limb paralysis and poor mental state around the 25th day after inoculation, and died quickly, with a median survival of 27 days. 1 / 24 The median survival time (MST) of mice was extended to 63.5 days, which was 2.4 times longer than that of the PBS group (***p<0.001), and was significantly better than that of Ps-VCR (MST: 33 days), Ps-Vol (MST: 43 days) and free VCR / Vol 1 / 24 (MST: 48.5 days) group (***p<0.001) (Figure 26B). On the 25th and 39th days, the tumor infiltration in the peripheral blood of mice was detected by flow cytometry. The results showed that on the 25th day, the tumor cells in the peripheral blood of mice in the PBS group accounted for 26.3%, and Ps-VCR inhibited the leukemia infiltration to a certain extent, accounting for 4.0%, while the other treatment groups effectively inhibited the proliferation of leukemia cells in vivo, and no obvious infiltration was observed in the peripheral blood (Figure 27A, B). On the 39th day, Ps-Vol and free VCR / Vol 1 / 24 The tumor infiltration rates in the peripheral blood of mice in the Ps-VCR / Vol 1 / 24 No tumor cells were detected in the peripheral blood of mice in the treatment group. 1 / 24 It can effectively inhibit the proliferation of leukemia cells and their infiltration into peripheral blood.

[0158] Then, on the 40th day, Ps-Vol, free VCR / Vol were dissected. 1 / 24 and Ps-VCR / Vol 1 / 24 The tumor infiltration in the peripheral blood, spleen, liver, lung and bone marrow of mice in the PBS group was detected by flow cytometry and compared with that of the PBS group and the Ps-VCR group at day 27 and day 34 (end of the experiment). The results showed that leukemia cells proliferated massively in the PBS and Ps-VCR groups and highly invaded the liver, spleen and bone marrow of the mice, with a tumor infiltration rate of more than 90%. The spleen was also enlarged, weighing about 600 mg (Figure 27C-E). Ps-Vol and free VCR / Vol 1 / 24 There were also a large number of leukemia cells infiltrating in the tissues and organs of the mice in the Ps-Vol group. In the spleen and liver, the leukemia cell infiltration was as high as 90%, and in the bone marrow, it was higher than 80%. 1 / 24The proportion of leukemia cells in the bone marrow, spleen, and liver of the two groups ranged from 74.5% to 86.6%, and the spleen weights of the two groups of mice were as high as 500 and 300 mg, respectively. 1 / 24 The infiltration rates of various organs of mice were all lower than 2%, which was significantly higher than that of PBS, Ps-VCR, Ps-Vol and free VCR / Vol. 1 / 24 The group decreased by 43.5-119.6 times. In addition, Ps-VCR / Vol 1 / 24 Mice in the control group did not experience splenomegaly, and their spleen weight was approximately 61 mg, which was 1 / 8 to 1 / 5 of that in the other control groups. These results suggest that Ps-VCR / Vol has a good safety profile and exhibits excellent synergistic antitumor activity in the orthotopic CCRF-CEM T-ALL model.

[0159] At the same time, the heart, liver, spleen, lung, kidney and other major organs and hind leg bones of each group were collected and fixed with 4% paraformaldehyde and embedded in paraffin. The pathological and histological analysis was performed by H&E. The results showed that the liver, spleen, bone marrow and lungs of the PBS group mice were almost completely invaded by T-ALL cells. Ps-VCR, Ps-Vol and free VCR / Vol were significantly increased. 1 / 24 The T-ALL cells in the liver, spleen, bone marrow and lung of the mice in the Ps-VCR / Vol group were reduced to a certain extent compared with those in the PBS group, but a large number of hematopoietic cells in the bone marrow disappeared (Figure 28A, B). 1 / 24 No obvious leukemia cells were found in the organs of the PBS group, which were no different from normal organ tissues, and no toxicity-related damage was observed. The above results are consistent with the infiltration results measured by flow cytometry. The massive proliferation of tumor cells in the bone marrow cavity will cause osteolytic destruction and cause bone pain. We further used micro-CT to observe the bone tissue structure of each group of mice. The results showed that a large number of trabeculae disappeared in the bone marrow cavity of mice in the PBS group, and there was osteolysis in the cortical bone (Figure 29A). Ps-VCR and Ps-Vol vesicle single drug groups and free VCR / Vol 1 / 24 Although the trabecular bone was improved compared with the PBS group, it was still at a low level. 1 / 24 It can significantly alleviate bone destruction. Quantitative analysis further showed that Ps-VCR / Vol 1 / 24 After treatment, the bone mineral density, bone volume fraction, bone surface area, trabecular thickness, and trabecular number of the mice's legs were significantly increased, and the trabecular separation was reduced, which was significantly better than that of the vesicle single drug group and the free VCR / Vol1 / 24 group (Figure 29B).

[0160] In order to further verify the Ps-VCR / Vol 1 / 24To investigate the synergistic anti-T-ALL effect in vivo, a patient-derived T-ALL orthotopic model (PDX) was established. 200 μL of patient-derived T-ALL cell suspension (1×10 6 ) were injected into 7-8 week old NOD.Cg-Prkdc cells via tail vein scid Il2rg tm1Vst / Vst(NPG) female mice, the day of inoculation was recorded as day 0 (Figure 30A). Grouping and administration began on the 3rd day after inoculation, with 6 mice in each group receiving PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, respectively. 1 / 24 and free VCR / Vol 1 / 24 The dosage and frequency of administration were consistent with those in the in situ CCRF-CEM mouse model. The weight and survival of the mice were continuously monitored during and after the administration, and the tumor infiltration in the peripheral blood of each group of mice was detected on days 24, 32, 39, 46, and 52. The results showed that 8.5% of the peripheral blood of the mice in the PBS group had tumor infiltration on day 24, and the tumor progressed rapidly. All mice died within 3 days, with a median survival of 25.5 days (Figure 30B-D). Ps-Vol, free VCR / Vol 1 / 24 The mice in the Ps-VCR and Ps-VCR groups showed obvious peripheral blood tumor infiltration on days 32 and 46, respectively, with leukemia cell percentages of 9.4%, 25.5%, and 8.9%, respectively, and median survival times of 39.5, 47, and 53 days, respectively. 1 / 24 No tumor infiltration was observed in the mice in the PBS group at 52 days. The mice were in good condition with a median survival of 71 days, which was 2.8 times longer than that in the PBS group (MST: 25.5 days) and significantly better than those in the Ps-VCR group (MST: 53 days) (***p<0.001), Ps-Vol group (MST: 39.5 days) (***p<0.001) and free VCR / Vol group. 1 / 24 (MST: 47 days) (***p<0.001) and other control groups. During the treatment period, the body weights of mice in all groups were normal and no obvious toxic side effects occurred (Figure 30E). The above results show that Ps-VCR / Vol 1 / 24 It has potent synergistic anti-T-ALL activity in vivo and has demonstrated excellent therapeutic effects in both in situ T-ALL CDX and PDX models.

[0161] 6. Ps-VCR / Vol 1 / 24 Synergistic anti-B-ALL activity in vivo

[0162] In order to further verify the Ps-VCR / Vol 1 / 24To demonstrate the synergistic anti-B-ALL effect in vivo, 200 μL Nalm-6-Luc B-ALL cell suspension (5×10 5 The orthotopic Nalm-6-Luc B-ALL model was established by injecting PBS and Ps-VCR / Vol into 7-8 week old female NCG mice through the tail vein. The day of inoculation was recorded as day 0 (Figure 30A). The mice were divided into groups and given PBS and Ps-VCR / Vol on the 5th day after inoculation. 1 / 24 The dosage and frequency of administration were consistent with those in the orthotopic CCRF-CEM mouse model. Each group consisted of 10 mice, 6 of which were used for weight and survival monitoring, and 4 for detecting tumor infiltration and observing tumor distribution and growth through in vivo imaging of mice. The results of mouse bioluminescence imaging showed that Ps-VCR / Vol 1 / 24 No tumor signal was observed in the mice of group B during the period of 14-23 days, and the bioluminescence signal was maintained at 5.2×10 5 p / s, which is comparable to the background signal of healthy mice (Figure 31B, C). However, the tumor signal in the PBS group mice grew rapidly, and the bioluminescence signal reached 1.1×10 10 p / s, is Ps-VCR / Vol 1 / 24 The expression of Ps-VCR / Vol 1 / 24 The survival of mice was significantly prolonged, with a median survival time of 63.5 days, which was 2.6 times longer than that of the PBS group (24 days) (Figure 31D). During the treatment period, there was no significant weight loss in the mice (Figure 31E).

[0163] On the 23rd day, the mice in each group were dissected and the tumor infiltration in the peripheral blood, spleen, liver, lung and bone marrow of the mice was detected by flow cytometry. The results showed that the tumor cells in the PBS group were highly infiltrated in various tissues and organs, with the infiltration rates in the liver, spleen, bone marrow, lung and peripheral blood being 80.9%, 72.8%, 58.9%, 36.6% and 28.0% respectively. In contrast, the Ps-VCR / Vol 1 / 24 The infiltration of each organ in the mice of the Ps-VCR / Vol group was less than 0.6%, which was 135-5890 times lower than that of the PBS group (Figure 32A, B). 1 / 24 The mice in the PBS group had no splenomegaly and their spleen weight was 46.5 mg, which was comparable to that of healthy mice. However, the spleen weight of the mice in the PBS group was as high as 175 mg, which was a significant difference from that of the Ps-VCR / Vol 1 / 24 The above results show that Ps-VCR / Vol 1 / 24 It has strong synergistic anti-B-ALL activity in vivo, greatly reducing tumor infiltration in mice, alleviating the tumor burden in mice, and significantly prolonging the survival of mice.

[0164] On the 23rd day, the spleen, liver, lung, heart, kidney and leg bones of mice in each group were collected for H&E staining analysis. The results showed that there were a large number of tumor cells in the spleen, liver and lung of mice in the PBS group, while in the Ps-VCR / Vol 1 / 24 No tumor cells were observed in these organs of the mice in the PBS group (Figure 33). In addition, the hearts and kidneys of the two groups of mice maintained good morphology and showed no damage to these two organs. In addition, the images of the leg bones showed that there was severe tumor cell invasion in the femur and tibia of the mice in the PBS group, and the hematopoietic tissue was severely damaged, resulting in a large number of hematopoietic cells disappearing. However, the Ps-VCR / Vol 1 / 24 The mice in the control group had complete hematopoietic function and hematopoietic tissue structure.

[0165] As an example, the Ps-VCR / Vol provided by the present invention is obtained by assembling and cross-linking amphiphilic block polymers, which has an asymmetric membrane structure, an outer shell of polyethylene glycol, a membrane layer of reversibly cross-linked hydrophobic polycarbonate, and an inner shell of KD z / AcKD z The preparation method of the drug-loaded vesicles of the present invention can be as follows: using vincristine sulfate, volacetidine, PEG-P (TMC-DTC)-KD z / AcKD z Ps-VCR / Vol was prepared using a solvent exchange method using α-aminobutyric acid (α-aminobutyric acid) as raw material. Both in vitro and in vivo experiments confirmed that the Ps-VCR / Vol provided by the present invention exhibited significant synergistic effects, significantly reducing the median lethal concentration (50%) of cells and, in particular, significantly increasing the median survival time of mice. Importantly, Ps-VCR / Vol exhibited a high safety profile even at high doses.

[0166] Those skilled in the art can make various other corresponding changes and deformations based on the technical solutions and concepts described above, and all of these changes and deformations should fall within the scope of protection of the claims of the present invention.

Claims

1. A drug-co-loaded polymer vesicle, It is characterized in that It is mainly prepared from amphiphilic block polymers and multiple anti-tumor drugs; the multiple anti-tumor drugs are two or more different anti-tumor drugs.

2. The drug-co-loaded polymer vesicle according to claim 1, It is characterized in that The structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-polypeptide segment.

3. The drug-loaded polymer vesicle according to claim 2, It is characterized in that The structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-KD z , where K is lysine and D is aspartic acid.

4. The drug-co-loaded polymer vesicle according to claim 2, It is characterized in that The structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-AcKD z , where K is lysine, D is aspartic acid, and Ac is acetyl.

5. The drug-co-loaded polymer vesicle according to claim 1, It is characterized in that At least one of the anti-tumor drugs is a microtubule inhibitor.

6. The drug-co-loaded polymer vesicle according to claim 5, It is characterized in that The microtubule protein inhibitor is any one or more of vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, and eribulin.

7. The drug-co-loaded polymer vesicle according to claim 1, It is characterized in that At least one of the anti-tumor drugs is an inhibitor targeting the oncogene Polo-like kinase 1.

8. The drug-co-loaded polymer vesicle according to claim 7, It is characterized in that The inhibitor targeting oncogene Polo-like kinase 1 is any one or more of volacetidine, reglucicetidine, ON01910, BI2536, HMN-214, and GSK461364.

9. The drug-co-loaded polymer vesicle according to claim 1, It is characterized in that The multiple anti-tumor drugs are a combination of a microtubule inhibitor and an inhibitor targeting the oncogene Polo-like kinase 1.

10. The drug-co-loaded polymer vesicle according to claim 9, It is characterized in that The microtubule inhibitor is vincristine sulfate, and the inhibitor targeting oncogene Polo-like kinase 1 is volacetide.

11. The drug-co-loaded polymer vesicle according to claim 9, It is characterized in that The feeding mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:(1-48).

12. The drug-co-loaded polymer vesicle according to any one of claims 1 to 11, It is characterized in that The hydrophilic segment in the amphiphilic block polymer is a polyethylene glycol segment, the hydrophobic segment is a random copolymer P(A-DTC), A is an ester monomer or a carbonate monomer, DTC is a disulfide five-membered ring carbonate unit; the ester monomer includes one or two of caprolactone and lactide; the carbonate monomer includes trimethylene carbonate.

13. The drug-co-loaded polymer vesicle according to any one of claims 1 to 11, It is characterized in that In the amphiphilic block polymer, the molecular weight of the hydrophilic segment is 2000-10000Da; the molecular weight of the hydrophobic segment is 2-10 times that of the hydrophilic segment; the molecular weight of PDTC is 10%-40% of the total molecular weight of the hydrophobic segment; and z is 1-20.

14. The drug-co-loaded polymer vesicle according to any one of claims 1 to 13, It is characterized in that The structure of the amphiphilic block polymer is any one of the following structures:

15. A drug-co-loaded polymer vesicle, It is characterized in that It is prepared from an amphiphilic block polymer, a tubulin inhibitor, and a targeted oncogene Polo-like kinase 1 inhibitor, wherein the structure of the amphiphilic block polymer is any one of the following structures: The microtubule protein inhibitor is vincristine sulfate, and the inhibitor targeting oncogene Polo-like kinase 1 is volacetide; preferably, the mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:(1-48).

16. A method for preparing the drug-co-loaded polymer vesicles according to any one of claims 1 to 15, It is characterized in that Using two or more anti-tumor drugs and amphiphilic block polymers as raw materials, the co-drug-loaded polymer vesicles are prepared by the solvent replacement method; or using microtubule inhibitors, inhibitors targeting oncogene Polo-like kinase 1, and amphiphilic block polymers as raw materials, the co-drug-loaded polymer vesicles are prepared by the solvent replacement method.

17. Use of the drug-co-loaded polymer vesicles according to any one of claims 1 to 15 in the preparation of anti-tumor drugs.

18. The use according to claim 17, It is characterized in that The anti-tumor drug includes a drug for treating acute myeloid leukemia or a drug for treating acute lymphocytic leukemia.

19. Use of the drug-co-loaded polymer vesicles according to any one of claims 1 to 15 in treating tumors.

20. The use according to claim 19, It is characterized in that Treatment of tumors includes treatment of acute myeloid leukemia or treatment of acute lymphoblastic leukemia.

21. A method for treating a tumor, It is characterized in that The drug-co-loaded polymer vesicles according to any one of claims 1 to 15 are used to treat tumors, or the drug-co-loaded polymer vesicles according to any one of claims 1 to 15 are used in combination with other drugs to treat tumors.

22. The method for treating tumors according to claim 21, It is characterized in that Treatment of tumors includes treatment of acute myeloid leukemia or treatment of acute lymphoblastic leukemia.

Citation Information

Patent Citations

  • Nano vesicles with pH and reduction dual sensitivity as well as preparation method and application thereof

    CN107840952A

  • Preparation method of nano delivery system between targeted redox-sensitive co-load chemotherapeutic drugs and P-gp resistance reversal agents

    CN108619526A

  • Drug-loaded polymer vesicle with asymmetric membrane structure, preparation method and application in preparation of drug for treating acute myeloid leukemia

    CN112076159A

  • Immune vesicle maytansine conjugate as well as preparation method and application thereof

    CN113244175A

  • Application of micromolecule drug-loaded polymer vesicle in preparation of drug for treating acute lymphocytic leukemia

    CN113827567A